반응식
[CH:1]12[CH2:7][CH:4]([CH2:5][CH2:6]1)[CH2:3][C@@H:2]2[NH:8][C:9]1[S:10][C:11]([CH2:16][CH:17]2[CH2:22][CH2:21][N:20]([C:23]([C:25]3[CH:26]=[C:27]([CH:39]=[CH:40][CH:41]=3)[O:28][CH2:29][CH2:30][NH:31][C:32](=[O:38])OC(C)(C)C)=[O:24])[CH2:19][CH2:18]2)([CH3:15])[C:12](=[O:14])[N:13]=1.NCCOC1C=[C:48]([CH:73]=[CH:74]C=1)[C:49](N1CCC(CC2(C)SC(N[C@H]3CC4CC3CC4)=NC2=O)CC1)=[O:50].O1C=CC(C(O)=O)=C1.CCN=C=NCCCN(C)C.C1C=CC2N(O)N=NC=2C=1.C(N(CC)CC)C>>[CH:1]12[CH2:7][CH:4]([CH2:5][CH2:6]1)[CH2:3][C@@H:2]2[NH:8][C:9]1[S:10][C:11]([CH2:16][CH:17]2[CH2:18][CH2:19][N:20]([C:23]([C:25]3[CH:26]=[C:27]([CH:39]=[CH:40][CH:41]=3)[O:28][CH2:29][CH2:30][NH:31][C:32]([C:73]3[CH:48]=[CH:49][O:50][CH:74]=3)=[O:38])=[O:24])[CH2:21][CH2:22]2)([CH3:15])[C:12](=[O:14])[N:13]=1참가 물질
7
실험 절차
The title compound was prepared according to the procedure described in the preparation of tert-butyl 2-(3-(4-((2-((2S)-bicyclo[2.2.1]heptan-2-ylamino)-5-methyl-4-oxo-4,5-dihydrothiazol-5-yl)methyl)piperidine-1-carbonyl)phenoxy)ethylcarbamate by using 5-((1-(3-(2-aminoethoxy)benzoyl)piperidin-4-yl)methyl)-2-((2S)-bicyclo[2.2.1]heptan-2-ylamino)-5-methylthiazol-4(5H)-one (93 mg, 0.19 mmol), 3-furoic acid (Aldrich, 39 mg, 0.35 mmol), EDCI (Aldrich, 74 mg, 0.38 mmol), HOBt (Aldrich, 5.2 mg, 0.038 mmol) and triethylamine (Aldrich, 39 mg, 0.38 mmol, 2.0 eq). The title compound was obtained as an off-white solid (89 mg). MS (ESI, pos. ion) m/z. 579 (M+H).
후처리
- customThe title compound was prepared
출처 및 근거
- ORD 기록
- ord-7f250aae5c6e460f92c0e6dd52144c49
- 출처 데이터셋
- uspto-grants-2013_09
- 특허 번호
- US08541592B2
연결된 노트
불러오는 중…